© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Aug 29, 2015, the consensus forecast amongst 5 polled investment analysts covering CTI BioPharma Corp advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts deteriorated on May 07, 2015. The previous consensus forecast advised investors to purchase equity in CTI BioPharma Corp.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 5 analysts offering 12 month price targets for CTI BioPharma Corp have a median target of 4.50, with a high estimate of 8.00 and a low estimate of 3.50. The median estimate represents a 181.25% increase from the last price of 1.60. View Full Financials
Dividend information is not available for CTi Biopharma Corp. View Full Financials
On Aug 06, 2015, CTI BioPharma Corp reported 2nd quarter 2015 losses of -0.19 per share. This result under-performed the -0.10 loss expectation of the 4 analysts following the company but was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Oct 27, 2015. View Full Interim Financials
|Average growth rate||-16.52 %|
CTI BioPharma Corp reported annual 2014 losses of -0.49 per share on Mar 12, 2015. View Full Annual Financials
|Average growth rate||+38.73 %|
CTI BioPharma Corp. had 2nd quarter 2015 revenues of 1.10m. This missed the 12.77m consensus estimate of the 4 analysts following the company. This was 18.09 % below the prior year's 2nd quarter results. View Full Interim Financials
|Average growth rate||+661.09 %|
CTI BioPharma Corp. had revenues for the full year 2014 of 60.08m. This was 2,496.24% above the prior year's results. View Full Annual Financials
|Average growth rate||+798.75 %|